RxSight, Inc. (NASDAQ:RXST) Insider Sells $139,500.00 in Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $45.00, for a total transaction of $139,500.00. Following the completion of the transaction, the insider now directly owns 42,246 shares of the company’s stock, valued at $1,901,070. This trade represents a 6.84 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, November 15th, Ilya Goldshleger sold 4,875 shares of RxSight stock. The shares were sold at an average price of $46.00, for a total transaction of $224,250.00.
• On Tuesday, November 12th, Ilya Goldshleger sold 1,330 shares of RxSight stock. The shares were sold at an average price of $46.13, for a total transaction of $61,352.90.
• On Wednesday, October 30th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $51.91, for a total transaction of $161,180.55.
• On Friday, October 25th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.79, for a total transaction of $154,349.00.
• On Monday, October 28th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.64, for a total transaction of $156,984.00.
• On Tuesday, October 22nd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.68, for a total transaction of $154,008.00.
• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total transaction of $155,529.45.
• On Wednesday, October 16th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.78, for a total transaction of $154,318.00.
• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.19, for a total transaction of $155,589.00.
• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.09, for a total transaction of $155,279.00.

RxSight Stock Performance

RXST traded down $0.39 on Monday, reaching $44.66. The company had a trading volume of 482,515 shares, compared to its average volume of 490,375. RxSight, Inc. has a fifty-two week low of $27.07 and a fifty-two week high of $66.54. The stock has a market cap of $1.80 billion, a P/E ratio of -53.81 and a beta of 1.19. The company’s fifty day moving average is $50.14 and its 200 day moving average is $53.15.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of RXST. RA Capital Management L.P. grew its position in shares of RxSight by 6.0% during the 3rd quarter. RA Capital Management L.P. now owns 3,916,825 shares of the company’s stock worth $193,609,000 after purchasing an additional 222,000 shares in the last quarter. Vanguard Group Inc. grew its position in shares of RxSight by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 1,524,510 shares of the company’s stock worth $78,634,000 after purchasing an additional 40,500 shares in the last quarter. State Street Corp grew its position in shares of RxSight by 8.3% during the 3rd quarter. State Street Corp now owns 817,671 shares of the company’s stock worth $40,417,000 after purchasing an additional 62,349 shares in the last quarter. Geode Capital Management LLC grew its position in shares of RxSight by 17.7% during the 3rd quarter. Geode Capital Management LLC now owns 817,117 shares of the company’s stock worth $40,398,000 after purchasing an additional 122,775 shares in the last quarter. Finally, Driehaus Capital Management LLC grew its position in shares of RxSight by 74.9% during the 2nd quarter. Driehaus Capital Management LLC now owns 706,162 shares of the company’s stock worth $42,490,000 after purchasing an additional 302,367 shares in the last quarter. Institutional investors and hedge funds own 78.78% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on RXST. Oppenheimer cut their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 6th. Wells Fargo & Company dropped their target price on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Needham & Company LLC reaffirmed a “buy” rating and issued a $66.00 target price on shares of RxSight in a report on Friday, September 13th. Stifel Nicolaus dropped their target price on shares of RxSight from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, August 6th. Finally, Jefferies Financial Group initiated coverage on shares of RxSight in a report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, RxSight currently has an average rating of “Buy” and a consensus price target of $61.63.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.